Scarica l'app Stockscreener
68.26
4.46%
-3.19
Dopo l'orario di chiusura:
68.94
0.68
+1.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
Piper Sandler maintains $93 target on Soleno stock post-VYKAT XR nod - Investing.com India
High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st
Soleno Therapeutics exec sells shares worth $9.5 million By Investing.com - Investing.com Australia
Soleno therapeutics director Matthew Pauls sells $424,797 in stock - Investing.com India
Soleno Therapeutics CCO sells shares worth $2.48m - Investing.com India
Soleno Therapeutics Executives and Director Sell Shares - TradingView
Soleno therapeutics’ SVP Yen Kristen sells $4.88 million in stock - Investing.com
Soleno Therapeutics CFO sells $4.88 million in stock - Investing.com
Soleno Therapeutics exec sells shares worth $9.5 million - Investing.com India
Soleno Therapeutics CEO sells $35.3 million in stock - Investing.com
Soleno Therapeutics CEO Anish Bhatnagar sells $35.3m in stock - Investing.com
Soleno Therapeutics Executives Sell Shares - TradingView
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock - Investing.com Australia
Soleno stock price target raised to $100 at H.C. Wainwright By Investing.com - Investing.com South Africa
Soleno stock price target raised to $100 at H.C. Wainwright - Investing.com
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock By Investing.com - Investing.com South Africa
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment - Markets Insider
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? - Insider Monkey
10 Stocks Outperform Broader Market Last Week - Insider Monkey
Soleno Therapeutics (NASDAQ:SLNO) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
Vivo opportunity sells $124 million in Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? - MSN
Guggenheim raises Soleno Therapeutics stock target to $81 By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Soleno Therapeutics! - TipRanks
Vivo opportunity sells $124 million in Soleno Therapeutics stock - Investing.com
Stifel raises Soleno stock target to $108 after FDA approval By Investing.com - Investing.com South Africa
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR - PR Newswire
Stifel raises Soleno stock target to $108 after FDA approval - Investing.com
Soleno Therapeutics price target raised to $108 from $74 at Stifel - TipRanks
FDA Approves First Therapy To Treat Hyperphagia in Prader-Willi Syndrome - Technology Networks
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Insider Monkey
Soleno Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
FDA Greenlights Soleno Therapeutics’ VYKAT XR for PWS Hyperphagia - geneonline.com
Oppenheimer lifts Soleno Therapeutics stock target to $105 By Investing.com - Investing.com Canada
Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease - Mugglehead
Biotech Zooms Into Breakout Zone On Hard-Fought Approval - Investor's Business Daily
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars - BioWorld MedTech
Drugmaker Soleno Soars on Approval to Treat Never Ending Hunger - Bloomberg.com
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SLNO) - Seeking Alpha
Soleno wins FDA approval for Prader-Willi hyperphagia treatment - Yahoo
Soleno Shares Are Up Today: What's Going On? - Benzinga
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome - Pharmaceutical Executive
Baird Raises Soleno Therapeutics' Price Target to $102 From $72, Outperform Rating Maintained - Marketscreener.com
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment - RagingBull
Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow - insights.citeline.com
Soleno stock skyrockets on FDA drug approval - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - FiercePharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - MSN
Soleno Therapeutics execs reap stock windfall after FDA approves rare disease drugSan Francisco Business Times - The Business Journals
Piper Sandler maintains $93 target on Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Soleno Skyrockets 40% on FDA Nod for VYKAT XR - Wall Street Pit
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga
Stifel maintains Soleno Therapeutics buy rating post FDA nod By Investing.com - Investing.com Australia
Behind the Scenes of Soleno Therapeutics's Latest Options Trends - Benzinga
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):